In spite of the compelling evidence supporting the protein free from brain PrP res inoculum. Our results indicate that PrP res generated in vitro under conditions in prion hypothesis, there is still considerable skepticism among scientists (Chesebro, 1998; Mestel, 1996; Soto which no brain-derived PrP res is present in the sample has the same structural and biochemical properties as and Castilla, 2004). It is widely accepted that the prion hypothesis can ultimately only be proven once infectivthe disease-associated protein. More importantly, we have shown that the PMCA-generated protein is infecity can be generated in a test tube. If the infectious agent is misfolded PrP res and its replication is protious to wild-type animals, leading to a disease that has clinical, histological, and biochemical properties that moted by interaction with PrP C , then it should be pos-are identical to the illness produced by the prion infecthe disease-associated misfolded protein ( Figure 2A 11 molecules. The 1,000, 2,500, 5,000 and 10,000 g/ml of PK ( Figure 2B ). amplified samples for the 10 −20 dilution were further diBoth proteins were highly resistant to these large PK luted and subjected to several rounds of PMCA sepaconcentrations, and, strikingly, the pattern of resistance rated by 100-fold dilutions to reach a final dilution of was virtually identical. This result is very significant bescrapie brain homogenate equivalent to 10 −40 (Figure cause protease resistance is one of the hallmark prop-1B). The serial replication of PrP res was additionally erties of disease-associated PrP, and its quantity correcontinued up to a 10 −55 dilution by performing a series lates tightly with infectivity (McKinley et al., 1983). of 1000-fold dilutions followed by 48 cycles of PMCA Several procedures have been reported to produce ( Figure 1C ). We conclude from these results that PMCA protease-resistant forms of PrP, but in most of these cases the protease resistance was only detected at low enables an infinite replication of PrP res in vitro. Interestconcentrations of the enzyme and was thus not compaingly, the signal can be fully recovered even after 1000-rable to the extent of protease resistance seen in bona fold dilution of the sample, suggesting that the amplifi- Figure 1 . The standard purification procedure based in vitro replication leads to a protein with identical on differential precipitation in detergents and protease degradation was used, and purity was estimated to be electrophoretic mobility and glycosylation pattern to Figure 1A ) were subjected to proteinase K (PK) digestion (50 g/ml for 60 min) and loaded onto SDS-PAGE. Immunoreactive bands were observed using Western blot and a 3F4 monoclonal antibody. Similar aliquots of both proteins were subjected to deglycosylation by treatment with peptide N-glycosidase F for 2 hr at 37°C. Western blot analyses of different dilutions before and after deglycosylation were performed. samples were able to convert high levels of PrP C to produce a similar amount of PrP res . The efficient conversion was lost under these conditions when the samples were diluted more than 160-fold (16,000-fold in total). This result indicates that an approximately 300-fold amplification rate was obtained for both brain and PMCA PrP res using 20 amplification cycles ( Figure 5A ). As described before, the rate of amplification depends upon the number of cycles performed (for example, a >6500-fold amplification was obtained when samples were subjected to 140 cycles), but, again, this rate was similar regardless of whether PrP res came from in vivo brain samples or from in vitro-produced protein (data not shown).
Finally, we studied whether the converting activity of in vitro-generated PrP res is as resistant to denaturation as has been reported for brain PrP res . Samples of brainderived and in vitro-generated PrP res were subjected to thermal denaturation by incubation at 100°C, 110°C, 120°C, and 140°C for 1 hr. Thereafter, these samples were used to trigger PrP res formation by diluting them into normal brain homogenate and performing 20 PMCA cycles. Generation of new PrP res was not altered by previously heating the samples at 100°C or 110°C, but this activity was dramatically reduced by incubating PrP res at 120°C and completely abolished after heating at 140°C ( Figure 5B ). Interestingly, the heat-resistance profile of both brain-derived and PMCA-produced PrP res was very similar, further supporting the hypothesis that the two forms resemble each other. this aim because, after many rounds of amplification following serial dilution of PrP res inoculum, we were able to produce a preparation of misfolded protein that was biochemically and structurally identical to braintypical prion rod-like structures that are 10 to 20 nm in diameter and 50 to 100 nm in length ( Figure S1 ), as derived PrP res but lacked any molecules of the initial scrapie-infected inoculum. To determine the infectious previously described Wille et al., 2000) . capability of in vitro-generated PrP res , groups of wildtype Syrian hamsters were inoculated intracerebrally A hallmark property of prions is their capability to sustain autocatalytic replication in vivo (Prusiner, 1998) .
(i.c.) with samples generated by 6 or 16 rounds of serial PMCA separated by 10-fold dilutions as described in Injection of brain extracts containing PrP res into an animal can further direct the conversion of normal PrP C , Figure 1 (see Figure S2 for a schematic description of the groups used in this study). Since at the first PMCA and the misfolded protein can in this way keep replicating across animals and generations (Prusiner, 1998) . the dilution of scrapie brain homogenate was 10 −4 , the final dilution of scrapie material in these groups corresThe results shown in In the animals infected with the 10 −10 dilution (group 6 Based on our experience with the 263K experimental model and the literature reports, the 10 −9 dilution of in Table 1 Therefore, we hypothesized that dilutions equivalent to 10 −10 and 10 −20 would not produce any detectable diswas newly generated protein (1 × 10 10 molecules). Strikingly, all of the animals in these two sets (groups 6 ease (Table 1) . This estimation was confirmed by the results obtained in our control groups (Table 1 ; groups and 7) showed typical signs of scrapie and died of the disease at around 170 days after inoculation (Table 1) . 1, 2, 3, and 4). Two different negative control groups Table 1 ) to begin PMCA amplification, so it serves as the double developed the disease at 100.2 days postinoculation control of the infectivity present in the sample prior to (Table 2) . No clinical signs were observed in negative any dilution and amplification as well as the infectivity control animals inoculated with normal brain homogeassociated with this amount of PrP res . The survival time nate. All animals in groups 2 and 3 of the experiment in was shorter than the one obtained with the equivalent Table 2 showed protease-resistant PrP in the brain after quantity of PMCA-generated PrP res , indicating that the postmortem analysis (data not shown). These results in vitro-generated misfolded protein was significantly indicate that the infectious agent generated in vitro is less infectious. We are currently doing infectivity titrastable over time. tion studies to find out exactly how much lower the infectivity in the samples is, but based on the survival Discussion time, in vitro-generated PrP res seems to be between 10 and 100 times less infectious than the same quantity of Compelling evidence has accumulated over the last brain-derived PrP res . several years in support of the protein-only hypothesis The clinical signs observed in the disease produced of prion propagation (Soto and Castilla, 2004; Prusiner, by the amplified samples were identical to those of the 1998). However, the prion concept is still highly controanimals inoculated with infectious brain material and versial, and it is widely accepted that the final proof for included hyperactivity, motor impairment, head wobthis hypothesis consists of the generation of infectious bling, muscle weakness, and weight loss. In order to material in vitro by inducing the misfolding of the prion evaluate whether the biochemical and neuropathologprotein (Soto and Castilla, 2004). Although extensively ical characteristics of the disease were also the same, attempted, the generation of infectious mammalian priwe performed a detailed comparative study of the ons in vitro has been elusive. Paradoxically, de novo brains of animals affected by the disease induced by generation of infectious proteins has been successfully brain-derived PrP res (group 5) and PMCA-generated done in a simpler system in yeast. A yeast prion has PrP res (groups 6 and 7). Brain samples from all the been defined as an infectious protein that behaves as animals in these three groups contained a large and a non-Mendelian genetic element, which transmits biosimilar quantity of PrP res , which has an identical glylogical information in the absence of nucleic acid. Dicosylation profile ( Figure 6A Table 1. of the prion hypothesis, but some experimental caveats fectivity. Our results represent the first time in which prion infectious material has been generated in vitro to remain to be addressed. The fact that the disease was originally transmitted to transgenic animals largely produce an in vivo disease in wild-type animals with characteristics identical to the disease produced by overexpressing the PrP gene and not to wild-type animals is a matter of concern because it is well known brain-isolated prions. These results provide some of the strongest evidence in support of the prion hypothesis. that this type of animals develops a prion-like disease spontaneously (Westaway et al., 1994; Castilla et al. ,
) into a group of six wild-type hamsters. All to inoculation). A positive control group of animals animals inoculated with this material exhibited typical (group 5) injected with this dilution of scrapie brain designs of the disease with a mean survival time of 136.5 veloped the disease with a mean survival time of 106 days (Table 2). Hamsters inoculated i.p. with the same days (Table 1). The material for this experiment and the dilution of brain homogenate from an animal originally dilution used correspond exactly to the sample utilized infected with brain-derived PrP res (group 5 in
The fact that a given quantity of in vitro-generated PrP res is associated with a lower degree of infectivity 2004a; Chiesa et al., 1998). In other words, the effect seen might just be an acceleration of the disease proas compared with brain-derived infectious material may explain the inconclusive results from Bieschke and cocess that was set to occur spontaneously at a later time. In this sense, an important missing control was workers ( protein isolated from scrapie-affected animals, including secondary structure, Western blot profile, protease in which a higher level of amplification (>200-fold) was obtained in a single round of PMCA, a significant inresistance, detergent insolubility, resistance to denaturation by heat and chaotropic agents, aggregation into crease in infectivity was observed (data not shown).
In this study we have further optimized the PMCA rod-like structures, efficiency in inducing the misfolding of the normal PrP C , and in vivo infectivity. These findprocedure to reach very high levels of PrP res conversion. Furthermore, we have been able to serially amplify ings indicate that PMCA is a valuable tool for studying the molecular basis of prion conversion and the factors PrP res in vitro indefinitely. As a result of many rounds of PMCA following serial dilution of brain infectious involved in this process as well as for identifying novel compounds that inhibit this pathological event. PMCA material, we have been able to generate large quantities of newly synthesized PrP res in the absence of any might also be useful for studying the mechanism of the species barrier and assessing whether the nature of the molecules of the brain-derived misfolded protein. This in vitro-generated PrP res isoform has identical bioprion strains is indeed encoded on the structure of the misfolded protein. Finally, the high levels of amplificachemical and structural properties to the protein used to begin the conversion, and, more importantly, the tion resulting from our improved and automated PMCA procedure may have important applications for TSE diin vitro-generated PrP res is clearly associated with in-technique after PK digestion, using plates coated with 3F4 anagnosis by allowing the highly sensitive detection of tibody.
PrP res .
Detergent Solubility Assay Experimental Procedures
Samples containing brain homogenate and in vitro-or in vivo-generated PrP res were incubated in the presence of 10% sarkosyl for Preparation of Tissue Homogenates 30 min at 4°C. Thereafter, samples were centrifuged at 100,000 × g Healthy and sick animals were perfused with phosphate-buffered for 1 hr in a Biosafe Optima MAX ultracentrifuge (Beckman Coulter), saline (PBS) plus 5 mM EDTA previous to harvesting the tissue. and the pellet of the centrifugation was then resuspended in conTen percent brain homogenates (w/v) were prepared in conversion version buffer plus electrophoresis sample buffer. Equivalent alibuffer (PBS containing 150 mM NaCl, 1.0% Triton X-100, 4 mM quots of supernatant and pellet were analyzed using immunoblot-EDTA, and the complete™ cocktail of protease inhibitors [Boehting. In some experiments, prior to the addition of sarkosyl, ringer Mannheim, Mannheim, Germany]). The samples were clarisamples were incubated with different concentrations of guanidine fied by a brief low-speed centrifugation (1500 rpm for 30 s) using hydrochloride for 2 hr at room temperature and shaken. Thereafter, an Eppendorf (Hamburg, Germany) centrifuge, model 5414.
sarkosyl was added and the soluble and insoluble proteins were separated using centrifugation. PrP res samples were first digested with PK as described above. at 4°C. The supernatant was discarded and the pellet was resusAfter addition of 10% sarkosyl (final concentration), samples were pended in 600 l of PBS containing 0.1% SB-314 and 10% NaCl centrifuged at 100,000 × g for 1 hr at 4°C, the supernatant was and sonicated. The resuspended pellet was layered over 600 l of discarded, and the pellet was resuspended in 100 l of glycopro-PBS containing 20% saccharose, 10% NaCl, and 0.1% SB-314 and tein denaturing buffer (New England Biolabs, Beverly, Massachucentrifuged for 3 hr at 4°C. The supernatant was discarded and the setts) and incubated for 10 min at 100°C. Thereafter, 26 l of 50 pellet was resuspended in 300 l of PBS containing 0.1% SB-314 mM sodium phosphate (pH 7.5) containing 1% nonidet P-40 and and sonicated again. After sonication the samples were incubated 3 l of peptide N-glycosidase F (New England Biolabs) was added. with PK (100 g/ml) for 2 hr at 37°C and shaken. The digested Samples were incubated for 2 hr at 37°C, the reaction was stopped sample was layered over 100 l of PBS containing 20% sarkosyl, by adding electrophoresis buffer, and samples were analyzed by 0.1% SB-314, and 10% NaCl and centrifuged for 1 hr 30 min at Western blot. 100,000 × g. The final pellet was resuspended in 100 l of PBS and sonicated. The sample was stored at −80°C. Purity was analyzed Samples of PrP res either highly purified from the brain or generated were incubated, without shaking, immersed in the water of the sonby PMCA amplification were resuspended in PBS, placed onto caricator bath.
bon formvar-coated 300-mesh nickel grids, and stained for 60 s with 2% uranyl acetate. Grids were analyzed using a Philips EM Protease-Resistance Assay 410 (FEI Company, Hillsboro, Oregon) electron microscope at 60 kV. The profile of PK sensitivity for in vitro-and in vivo-generated PrP res was studied by subjecting samples to incubation for 60 min PrP res Thermal Inactivation at 45°C with different concentrations of PK ranging from 0 to 10,000 Equivalent samples of brain homogenates containing in vivog/ml. The digestion was stopped by adding electrophoresis samderived and PMCA-generated PrP res were incubated for 20 min at ple buffer. For all other experiments involving PK digestion, the different temperatures (room temperature, 100°C, 110°C, 120°C, standard conditions used consisted of incubating the samples with and 140°C). Thereafter, aliquots were taken, diluted into normal 50 g/ml of the enzyme for 60 min at 45°C. brain homogenate, and subjected to PMCA amplification. Formation of new PrP res was monitored using Western blot after PK diPrP res Quantification gestion. PrP res concentration was estimated by Western blotting followed by densitometric analysis, using known concentrations of hamster recombinant PrP C (Prionics Inc, Zurich, Switzerland). To obtain a In Vivo Infectivity Studies Syrian golden hamsters were used. Animals were 4 to 6 weeks old reliable and robust quantification, we ran several different dilutions of the sample in the same gel as the standard, thus avoiding artiat the time of inoculation. Anesthesized animals were injected stereotaxically in the right hippocampus with 1 l of the sample using facts due to saturation of the signal or to too weak a signal. In some selected samples, quantification was confirmed by single ELISA a computerized perfusion machine that delivered the sample into the brain at a rate of 0.1 l/min. For the second-passage experi
